These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 22994556)

  • 1. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care.
    McCombe JA; Vivithanaporn P; Gill MJ; Power C
    HIV Med; 2013 Feb; 14(2):99-107. PubMed ID: 22994556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.
    Vassallo M; Durant J; Lebrun-Frenay C; Fabre R; Ticchioni M; Andersen S; DeSalvador F; Harvey-Langton A; Dunais B; Cohen-Codar I; Montagne N; Cua E; Fredouille-Heripret L; Laffon M; Cottalorda J; Dellamonica P; Pradier C
    HIV Med; 2015 Aug; 16(7):431-40. PubMed ID: 25981452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
    Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Montreal Cognitive Assessment Performance in HIV/AIDS: Impact of Systemic Factors.
    Koenig N; Fujiwara E; Gill MJ; Power C
    Can J Neurol Sci; 2016 Jan; 43(1):157-62. PubMed ID: 26635008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurocognitive functioning in pediatric human immunodeficiency virus infection: effects of combined therapy.
    Shanbhag MC; Rutstein RM; Zaoutis T; Zhao H; Chao D; Radcliffe J
    Arch Pediatr Adolesc Med; 2005 Jul; 159(7):651-6. PubMed ID: 15996999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS.
    Vivithanaporn P; Nelles K; DeBlock L; Newman SC; Gill MJ; Power C
    J Neurol Sci; 2012 Jan; 312(1-2):45-51. PubMed ID: 21925684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
    Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
    Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.
    Cingolani A; Cozzi Lepri A; Castagna A; Goletti D; De Luca A; Scarpellini P; Fanti I; Antinori A; d'Arminio Monforte A; Girardi E
    Clin Infect Dis; 2012 Mar; 54(6):853-61. PubMed ID: 22157323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS).
    Farinpour R; Miller EN; Satz P; Selnes OA; Cohen BA; Becker JT; Skolasky RL; Visscher BR
    J Clin Exp Neuropsychol; 2003 Aug; 25(5):654-70. PubMed ID: 12815503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of HIV-1 viral load and CD4 lymphocyte count as determinants of progression to AIDS and survival].
    Romeu J; Balagué M; Ruiz L; Marfil S; Puig T; Arnó A; Veny A; Tural C; Sirera G; Clotet B
    Med Clin (Barc); 1998 Jun; 110(20):761-7. PubMed ID: 9666416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive disorders in HIV-infected patients: are they HIV-related?
    Bonnet F; Amieva H; Marquant F; Bernard C; Bruyand M; Dauchy FA; Mercié P; Greib C; Richert L; Neau D; Catheline G; Dehail P; Dabis F; Morlat P; Dartigues JF; Chêne G;
    AIDS; 2013 Jan; 27(3):391-400. PubMed ID: 23079813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.